{"id":63004,"date":"2026-04-13T19:53:19","date_gmt":"2026-04-13T11:53:19","guid":{"rendered":"https:\/\/flcube.com\/?p=63004"},"modified":"2026-04-13T19:53:20","modified_gmt":"2026-04-13T11:53:20","slug":"fda-accepts-nda-for-telixs-pixclara-tlx101-px-glioma-imaging-agent-decision-expected-september-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63004","title":{"rendered":"FDA Accepts NDA for Telix&#8217;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026"},"content":{"rendered":"\n<p><strong>Telix Pharmaceuticals Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TLX:ASX\">ASX: TLX<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TLX:NASDAQ\">NASDAQ: TLX<\/a>), the Australian partner of <strong>Grand Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG: 0512<\/a>), announced that the U.S. Food and Drug Administration (<strong>FDA<\/strong>) has accepted its New Drug Application (<strong>NDA<\/strong>) for <strong>Pixclara<\/strong> (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (<strong>PET<\/strong>) tracer is designed for imaging <strong>glioma<\/strong>, a type of brain cancer. The FDA has set a target action date of <strong>September 11, 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-details\">Regulatory &amp; Product Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Pixclara (TLX101-Px, fluotyrosine F18 \/ 18F-FET)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PET imaging of glioma (brain cancer)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>FDA NDA Accepted<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>September 11, 2026<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Targets L-type amino acid transporters LAT1\/LAT2 on tumor cells<\/td><\/tr><tr><td><strong>Theranostic Link<\/strong><\/td><td>Companion diagnostic for Telix\u2019s therapeutic candidate TLX101-Tx<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-context\">Strategic Partnership Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Grand Pharma Alliance:<\/strong> In June 2022, <strong>Grand Pharmaceutical<\/strong> secured exclusive rights from Telix in a <strong>$250 million deal<\/strong> to develop, manufacture, and commercialize a portfolio of radiopharmaceutical candidates\u2014including <strong>TLX591, TLX250, and TLX101<\/strong>\u2014in Greater China (Mainland China, Hong Kong, Macau, and Taiwan).<\/li>\n\n\n\n<li><strong>Integrated Theranostic Platform:<\/strong> Pixclara (TLX101-Px) serves as the diagnostic arm of a <strong>theranostic pair<\/strong>. By visualizing LAT1\/LAT2 expression, it enables precise <strong>patient selection<\/strong> and <strong>treatment response monitoring<\/strong> for Telix\u2019s corresponding LAT1-targeted therapeutic, <strong>TLX101-Tx<\/strong>.<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> A successful U.S. approval would provide critical global validation for the platform, significantly enhancing the strategic value of Grand Pharma\u2019s licensed assets in its core markets and supporting future regulatory efforts across Asia.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressing Diagnostic Gaps:<\/strong> Current standard imaging struggles to differentiate true tumor progression from treatment-related effects (e.g., pseudoprogression) in glioma patients. Pixclara\u2019s specific targeting of LAT1\/LAT2 offers the potential for superior diagnostic accuracy.<\/li>\n\n\n\n<li><strong>Radiopharma Milestone:<\/strong> This NDA acceptance marks a pivotal achievement for Telix and its partner Grand Pharma, representing a major step toward establishing a commercial theranostic franchise in neuro-oncology.<\/li>\n\n\n\n<li><strong>Key Catalyst:<\/strong> The PDUFA date of September 11, 2026, stands as a significant near-term catalyst for both companies, with approval paving the way for a U.S. launch and reinforcing the global credibility of their partnership.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on an FDA filing acceptance. There can be no assurance that the NDA will be approved by the PDUFA date or at all. The development and commercial success of Pixclara and its associated therapeutic are subject to regulatory, clinical, and market risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2403,683,1184,38,4235,2402],"class_list":["post-63004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-asx-tlx","tag-grand-pharmaceutical","tag-hkg-0512","tag-market-approval-filings","tag-nasdaq-tlx","tag-telix-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Accepts NDA for Telix&#039;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63004\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts NDA for Telix&#039;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026\" \/>\n<meta property=\"og:description\" content=\"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63004\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T11:53:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T11:53:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Accepts NDA for Telix&#8217;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026\",\"datePublished\":\"2026-04-13T11:53:19+00:00\",\"dateModified\":\"2026-04-13T11:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1303.webp\",\"keywords\":[\"ASX: TLX\",\"Grand Pharmaceutical\",\"HKG: 0512\",\"Market approval filings\",\"NASDAQ: TLX\",\"Telix Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63004#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63004\",\"name\":\"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1303.webp\",\"datePublished\":\"2026-04-13T11:53:19+00:00\",\"dateModified\":\"2026-04-13T11:53:20+00:00\",\"description\":\"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63004\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1303.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63004#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts NDA for Telix&#8217;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63004","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026","og_description":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.","og_url":"https:\/\/flcube.com\/?p=63004","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T11:53:19+00:00","article_modified_time":"2026-04-13T11:53:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63004#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63004"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Accepts NDA for Telix&#8217;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026","datePublished":"2026-04-13T11:53:19+00:00","dateModified":"2026-04-13T11:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63004"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63004#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","keywords":["ASX: TLX","Grand Pharmaceutical","HKG: 0512","Market approval filings","NASDAQ: TLX","Telix Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63004#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63004","url":"https:\/\/flcube.com\/?p=63004","name":"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63004#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63004#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","datePublished":"2026-04-13T11:53:19+00:00","dateModified":"2026-04-13T11:53:20+00:00","description":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512), announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Pixclara (TLX101-Px, fluotyrosine F18 or 18F-FET). This investigational positron emission tomography (PET) tracer is designed for imaging glioma, a type of brain cancer. The FDA has set a target action date of September 11, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63004#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63004"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63004#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","width":1080,"height":608,"caption":"FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63004#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts NDA for Telix&#8217;s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63004"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63004\/revisions"}],"predecessor-version":[{"id":63006,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63004\/revisions\/63006"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63005"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}